Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle
- PMID: 15086870
- DOI: 10.1111/j.1365-2982.2004.00517.x
Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle
Abstract
Otilonium bromide (OB) is used as an intestinal antispasmodic. The mechanism of action of OB is not completely understood. As Ca(2+) entry into intestinal smooth muscle is required to trigger contractile activity, our hypothesis was that OB blocked Ca(2+) entry through L-type Ca(2+) channels. Our aim was to determine the effects of OB on Ca(2+), Na(+) and K(+) ion channels in human jejunal circular smooth muscle cells and on L-type Ca(2+) channels expressed heterologously in HEK293 cells. Whole cell currents were recorded using standard patch clamp techniques. Otilonium bromide (0.09-9 micromol L(-1)) was used as this reproduced clinical intracellular concentrations. In human circular smooth muscle cells, OB inhibited L-type Ca(2+) current by 25% at 0.9 micromol L(-1) and 90% at 9 micromol L(-1). Otilonium bromide had no effect on Na(+) or K(+) currents. In HEK293 cells, 1 micromol L(-1) OB significantly inhibited the expressed L-type Ca(2+) channels. Truncation of the alpha(1C) subunit C and N termini did not block the inhibitory effects of OB. Otilonium bromide inhibited Ca(2+) entry through L-type Ca(2+) at concentrations similar to intestinal tissue levels. This effect may underlie the observed muscle relaxant effects of the drug.
Similar articles
-
Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon.Neurogastroenterol Motil. 2004 Apr;16(2):175-83. doi: 10.1111/j.1365-2982.2004.00518.x. Neurogastroenterol Motil. 2004. PMID: 15086871
-
Effect of otilonium bromide on contractile patterns in the human sigmoid colon.Neurogastroenterol Motil. 2010 Jun;22(6):e180-91. doi: 10.1111/j.1365-2982.2010.01495.x. Epub 2010 Mar 31. Neurogastroenterol Motil. 2010. PMID: 20367799
-
T-type Ca(2+) channel modulation by otilonium bromide.Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G706-13. doi: 10.1152/ajpgi.00437.2009. Epub 2010 Mar 4. Am J Physiol Gastrointest Liver Physiol. 2010. PMID: 20203058 Free PMC article.
-
Pharmacological studies on otilonium bromide.Ital J Gastroenterol. 1991 Nov;23(8 Suppl 1):56-9. Ital J Gastroenterol. 1991. PMID: 1661629 Review.
-
Otilonium Bromide: A Drug with a Complex Mechanism of Action.Curr Pharm Des. 2018;24(16):1772-1779. doi: 10.2174/1381612824666180507122935. Curr Pharm Des. 2018. PMID: 29732965 Review.
Cited by
-
Irritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity.Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0044321. doi: 10.1128/AAC.00443-21. Epub 2021 Jul 19. Antimicrob Agents Chemother. 2021. PMID: 34280019 Free PMC article.
-
Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium.J Neurogastroenterol Motil. 2014 Jan;20(1):113-21. doi: 10.5056/jnm.2014.20.1.113. Epub 2013 Dec 30. J Neurogastroenterol Motil. 2014. PMID: 24466452 Free PMC article.
-
IBS and the role of otilonium bromide.Int J Colorectal Dis. 2013 Mar;28(3):295-304. doi: 10.1007/s00384-012-1598-0. Epub 2012 Nov 22. Int J Colorectal Dis. 2013. PMID: 23178991 Review.
-
Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.Therap Adv Gastroenterol. 2014 Jul;7(4):156-66. doi: 10.1177/1756283X14525250. Therap Adv Gastroenterol. 2014. PMID: 25057296 Free PMC article. Review.
-
Targeting ion channels for the treatment of gastrointestinal motility disorders.Therap Adv Gastroenterol. 2012 Jan;5(1):5-21. doi: 10.1177/1756283X11415892. Therap Adv Gastroenterol. 2012. PMID: 22282704 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous